Welcome to our dedicated page for Foghorn Therapeutics SEC filings (Ticker: FHTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Foghorn Therapeutics Inc. (FHTX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Foghorn is a clinical-stage biotechnology company listed on The Nasdaq Global Market, and its common stock is registered under the symbol FHTX, as reflected in multiple Form 8-K filings.
For investors analyzing FHTX, Form 8-K filings are especially important. Recent 8-Ks have reported quarterly financial results, including collaboration revenue from the company’s strategic agreement with Lilly, research and development and general and administrative expenses, and net loss figures. Other 8-Ks describe material corporate events such as leadership changes in the Chief Financial Officer role, interim CFO appointments through Danforth Advisors, and updates on presentations and investor materials furnished under Regulation FD.
Foghorn also uses 8-K filings to furnish investor presentations and pipeline updates, including detailed summaries of its chromatin-focused programs. These documents outline the status of FHD-909 (LY4050784), a first-in-class SMARCA2 selective inhibitor in Phase 1 trials for SMARCA4-mutated cancers, as well as selective CBP, EP300, and ARID1B degrader programs moving through preclinical and IND-enabling stages. Additional 8-K disclosures cover facility leases in Massachusetts for principal executive offices and research, development, manufacturing, and related uses.
On this page, new SEC filings are captured as they are made available on EDGAR, allowing users to track Foghorn’s current reports, financial updates, and other material events in one place. Stock Titan’s interface is designed to make it easier to review the contents of lengthy filings and locate key items such as results of operations, material agreements, leadership changes, and Regulation FD presentations.
By using this filings hub, investors and researchers can follow how Foghorn Therapeutics reports its financial condition, corporate actions, clinical and preclinical program disclosures, and capital markets activity through official SEC documents, including 8-Ks and any related registration statements referenced in company press releases.
Foghorn Therapeutics (FHTX) filed an 8-K announcing pipeline updates for its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs. On October 30, 2025, the company hosted a conference call and webcast to review these updates, and furnished the related presentation as Exhibit 99.1 under Regulation FD.
Foghorn also issued a press release on the same date, attached as Exhibit 99.2 and incorporated by reference. The furnished materials are not deemed filed for liability purposes under Section 18 of the Exchange Act. The disclosure includes customary forward-looking statements language referencing clinical trials, product candidates, and risk factors in the company’s most recent Form 10-K.
Foghorn Therapeutics Inc. furnished a new investor presentation dated September 2025 as an exhibit to a current report. The company plans to use this presentation in meetings and presentations with investors, offering an overview of its business and outlook in a slide format.
The investor materials are provided under a Regulation FD disclosure, which means they are being made available to the public to ensure fair access to information. The company states that the presentation is being furnished, not filed, so it is not subject to certain legal liabilities under the securities laws unless specifically incorporated into other documents.
Foghorn Therapeutics (FHTX) Q2-25 10-Q highlights:
- Revenue: Collaboration income with Eli Lilly rose 10% YoY to $7.6 m; H1-25 revenue up 13% to $13.5 m.
- Expenses: R&D fell 8% to $21.8 m and G&A fell 6% to $6.9 m, driving a 15% narrower operating loss of $21.1 m.
- Net loss: Q2 loss improved to $17.9 m (-$0.28/sh) from $23.0 m (-$0.45/sh) last year; H1 loss narrowed to $36.8 m (-$0.58/sh).
- Liquidity: Cash & cash equivalents $72.6 m; marketable securities $126.1 m; combined liquid resources $198.7 m. Management expects runway ≥12 months despite $45 m operating cash burn in H1.
- Balance sheet: Deferred revenue declined to $266.6 m as collaboration work progresses; total liabilities $302.9 m exceed assets $226.2 m, producing a $76.7 m shareholders’ deficit.
- Operations: FHD-909 (SMARCA2) transitioned to Lilly with 50/50 cost share; FHD-286 development discontinued (2024). New 10-year Watertown lease signed; Cambridge lease partially reduced, lowering future obligations by $8.5 m.
Key takeaways: Expense discipline and steady milestone revenue trimmed losses, but the pre-commercial company remains cash-burning and carries a negative equity position. Progress of the Lilly collaboration and access to additional capital remain critical catalysts.